Among patients with KRAS G12C-mutant cancers treated with adagrasib monotherapy in the KRYSTAL-1 trial, Awad et al. (2021) showed that patients acquired novel secondary KRAS mutations within the adagrasib-binding pocket. The gene discussed is KRAS; the disease is cancer.